|
Synonyms: Bavencio® | MSB-0010718C | MSB0010718C
avelumab is an approved drug (EMA & FDA (2017))
Compound class:
Antibody
Comment: Avelumab is a programmed death-ligand 1 (PD-L1; CD274) blocking human IgG1 lambda monoclonal antibody . It is the first drug approved for the treatment of Merkel cell carcinoma (MCC).
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. |
Classification  |
|
| Compound class | Antibody |
| Ligand families/groups | Immune checkpoint modulators |
| Approved drug? | Yes (EMA & FDA (2017)) |
| International Nonproprietary Names |
|
| INN number | INN |
| 10062 | avelumab |
| Synonyms |
| Bavencio® | MSB-0010718C | MSB0010718C |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 512 |
| Other databases | |
| GtoPdb PubChem SID | 252827393 |
| Search PubMed clinical trials | avelumab |
| Search PubMed titles | avelumab |
| Search PubMed titles/abstracts | avelumab |
